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CLINICAL INVESTIGATION
Excess PTH in CRF induces pulmonary calcification, pulmonary
hypertension and right ventricular hypertrophy
Mortr Aiipj., ROBERT R. BARNDT, AZIZULLAH N. ANSARI, JOHN G. MOHLER,
and SHAUL G. MASSRY
Division of Nephrology, and Pulmonaiy Medicine, the Departments of Medicine and Nuclear Medicine, Universily of Southern California School of
Medicine, Los Angeles, California, USA
Excess P'fH in CRF induces pulmonary calcification, pulmonary
hypertension and right ventricular hypertrophy. Calcification of the lungs
occurs in chronic renal failure (CRF) and may adversely affect both
pulmonary and right ventricular function. The present study examined the
role of excess parathyroid hormone (PTH) in the genesis of pulmonary
calcifications in dogs with experimental CRF and evaluated calcium
content of lungs, diffusing lung capacity (DCO), mean pulmonary artery
pressure (MPAP), right ventricular pressure (RVP), and right ventricular
hypertrophy (RVH) in six normal, six with CRF, and six thyroparathy-
roidectomized (CRF-PTX) dogs. CRF-PTX animals were maintained
normocalcemic and euthyroid. The degree and duration of CRF were not
different between the two groups with CRF. The mean value of the serum
PTH in CRF dogs was 166 42 j.dEq/ml, but was undetectable in
CRF-PTX animals. Thallium scan provided evidence consistent with RVH
in CRF dogs but not in CRF-PTX animals. Calcium content of lungs was
markedly elevated in CRF dogs (7656 1657 mg/kg dry wt) but modestly
increased in CRF-PTX (1057 117 mg/kg dry wt) as compared to normal
(673 34 mg/kg dry wt). RVP and MPAP were significantly (P < 0.01)
higher and DCO significantly lower in CRF dogs than in normal or
CRF-PTX animals. These parameters were not different in the latter two
group of dogs. In three additional dogs with CRF of one year duration
which were followed for an additional year after parathyroidectomy, these
abnormalities were corrected. The data demonstrate that: (1) pulmonary
calcification of CRF is, at least partly, due to the secondary hyperpara-
thyroidism; (2) this pulmonary calcification impairs lung function and
exerts adverse effects on the right ventricle; and (3) prevention of the
secondary hyperparathyroidism of CRF by PTX prevented and/or re-
versed these derangements.
Pulmonary metastatic calcification has been reported in pa-
tients with chronic renal failure (CRF) and those treated with
hemodialysis [1—5]. This complication occurs in about 50% of
patients with CRF who have evidence of other soft tissue calcifi-
cations, but pulmonary calcification is rarely diagnosed clinically
or by chest X-ray [1, 3, 4]. In one study, 61% of patients receiving
long-term maintenance hemodialysis therapy and who had normal
chest roentgenograms demonstrated abnormal uptake of Techne-
tium-99 diphosphonate by the lung, indicating the presence of
pulmonary calcification [5]. The latter may lead to progressive
respiratory distress and restrictive changes in pulmonary function
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[3]. Also, calcium deposition in the lungs may increase pulmonary
artery pressure and consequently affect right heart function.
One prominent biochemical abnormality in renal failure is
secondary hyperparathyroidism in humans [6—8] and animals [9,
10], and marked elevation in blood levels of parathyroid hormone
(PTH) [6—10]. PTH is known to enhance the entry of calcium into
many cells [11—16], and chronic exposure to excess blood levels of
PTH is associated with increased calcium content of many tissues
[17—23]. It is, therefore, possible that the state of secondary
hyperparathyroidism is also responsible for the pulmonary calci-
fication in CRF.
The present study examined the role of chronic excess of PTH
in the genesis of pulmonary calcifications in dogs with experimen-
tal CRF, and evaluated the pathophysiological consequences of
pulmonary calcification on the functions of the lungs and the right
heart.
Methods
A total of 21 female mongrel dogs weighing 18 to 26 (21.5
0.5) kg were studied. All animals received the same diet, which
provided 78 g of protein, 60 g of fat, 5 g of calcium, and 3 g of
phosphorous (Kal Kan; Kal Kan Foods Co., Inc., Vernon, CA,
USA). All dogs underwent episiotomy to permit easy access to the
bladder for the measurement of creatinine clearance in the awake
state. Baseline studies included the measurements of the plasma
concentration of sodium, potassium, bicarbonate, total calcium,
magnesium and phosphorous and free thyroxine index, serum
levels of parathyroid hormone (PTH), and endogenous creatinine
clearance.
After these baseline studies, fifteen animals underwent left
renal infarction by ligation of five of the six branches of the left
renal artery, and in six of the dogs, surgical thyroparathyroidec-
tomy (PTX) was also performed at the same time. The success of
the latter procedure was ascertained by a fall in the serum calcium
of at least 2 mg/dl. The diet of the thyroparathyroidectomized
animals was supplemented with 5 g/day of calcium carbonate to
maintain normocalcemia and with thyroxine (0.1 mg daily, 5
days/week) to prevent hypothyroidism. Three weeks later, all of
the dogs were subjected to right nephrectomy. Thus, this protocol
provided two groups of dogs with CRF: nine with intact parathy-
roid glands (CRF) and the other six without parathyroid glands
(CRF-PTX). These animals were followed for 52 to 68 weeks. In
three of CRF dogs, PTX was done after 52 weeks and these
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animals were maintained for additional 52 weeks thereafter.
During the period of CRF, measurements of plasma concentra-
tions of calcium, phosphorous, and magnesium were made several
times. Plasma electrolytes and creatinine, and serum PTH, and
creatinine clearance were also measured at the end of the study.
We did not encounter difficulty in maintaining CRF or CRF-PTX
dogs, and the mortality was about 15%. A third group of six
normal dogs were also studied.
The plasma concentrations of phosphorous, creatinine, and
bicarbonate were determined by an autoanalyzer (Technicon
Instrument Corp., Tarrytown, NY, USA), those of sodium and
potassium were measured with an IL flame photometer model 343
(Instrumentation Laboratory, Inc., Lexington, MA, USA), and
concentrations of calcium and magnesium were estimated with an
atomic absorption spectrophotometer model 503 (Perkin-Elmer
Corp; Norwalk, CT, USA). The serum levels of PTH was deter-
mined with radioimmunoassay using sheep antiserum 478 (sup-
plied by Dr. Claude Arnaud), '251-labeled bovine PTH, and
pooled sera from patients with renal failure as a standard. This
antibody reacts predominantly with an immunologic determinant
in the carboxyterminal fragment, and it will detect both the intact
hormone and carboxyterminal fragment. The value for this assay
in 63 samples from normal subjects ranged from undetectable to
15 tlEq/ml (mean SE, 7.5 0.7) and PTH was detectable in 33
of 63 (52%) of normal subjects. Elevated blood levels of PTH
were found in 60 patients with chronic renal failure. The lower
limit of detectability was 1 tlEqIml. The assay was validated for
measurements of PTH in dog serum by comparing PTH values in
two separate assays using both pooled human and pooled canine
uremic sera as standards. The values for PTH displayed a linear
correlation with r = 0.99 for data from sera of normal dogs and an
r of 0.92 for data from sera of uremic dogs. The details of this
assay has been described previously by our laboratory [9]. Free
thyroxine index is calculated as the product ofT3 uptake ratio and
T4.
The following studies were performed before the sacrifice of
the animals:
(1.) Evaluation of right ventricular hypertrophy with thallium scan
This study was performed as follows. A butterfly needle was
inserted in one of the hind limbs and properly secured. The dogs
were anesthetized with intravenous surital (15 mg/kg/body wt),
and then intubated. The thallium scan was performed in these
dogs after they were rested for 30 minutes. After the bolus
injection of 2 mCi of thallium-201 (T1-201), planar images were
obtained using a standard gamma camera and low energy colli-
mator. The images were obtained in anterior, and 45° left anterior
oblique projection with 200 K per each image.
(2.) Measurement of diffusing capacity of lung (DCO)
The dogs were anesthetized using intravenous surital (15 mg/
kg/body wt). A low dead space (30 ml) directional valve was
placed on the airway which enabled the measurement of ventila-
tory volume and frequency, as well as the volume of carbon
monoxide (CU) consumed during the test. The dogs were allowed
to breathe spontaneously, and all measurements were made after
the dogs reached a steady state of gas exchange following five
minutes of spontaneous breathing while attached to the set-up.
Gases of known concentration for CU, nitrogen and oxygen were
placed on the inspired side of the circuit, and the expired gas was
collected for an exact period of five minutes. The CO concentra-
tions were determined by a carefully calibrated infrared CO
analyzer, which is able to determine the fractional value of each
sample to six decimal places. Measurements of the exhaled gas
concentrations was made in duplicates with the requirement that
each sample must agree with the other by less than 0.000005
fractional parts. The values which satisfied this criterion were
averaged and used in the calculations. The fractional concentra-
tions of exhaled carbon dioxide (FE02) were also determined by
mass spectrometer to a fractional value of four decimal places,
with a requirement that duplicate samples agree to within 0.0004
parts before being averaged. During the last minute of the testing
period, an arterial blood sample was withdrawn from an arterial
cannula placed in the femoral artery for the determination of the
arterial P02. Each blood sample was measured on two blood gas
machines which were calibrated before and after analysis. Each
machine value was required to agree within a 2 torr before the
samples were averaged and used in the calibrations. In addition,
the fractional concentration of exhaled oxygen (FE02) was also
determined so that the respiratory exchange ratio (RER) could be
determined to insure that the dog was indeed in a steady state
when the sample was taken.
The calculation of the steady-state diffusing capacity (DCO)
was made by the method of Filley, Macintosh and Wright [24]
using the equation: DCO = VCO/PACO where VCO = volume
of CO exhaled in mi/mm and PACO = alveolar CO pressure
[these two parameters were calculated as follows; PACO =
PICO - (PACO2[PECO2) X (PICO - PECO)], and VCO = VE(FI0 — FEo), PICO = inhaled CO, PACO2 = alveolar CO2
pressure, PECO2 = mixed expired CO2, PECO = exhaled CU,yE = minute ventilation, FI0 fraction concentration of
inhaled CO, and FE0 = fraction concentration of exhaled CU;
and VCO values are corrected to STPD (standard temperature,
pressure and water vapor pressure).
(3,) Measurements of pulmonaiy artery pressure (PAP), and right
ventricular pressure (RI'?)
The dogs were anesthetized by intravenous administration of
surital (15 mg/kg/body wt) and then intubated. The right jugular
vein was isolated by a cutdown. A #7 French Swan-Ganz flow
directed catheter was inserted and was placed into a pulmonary
vein position by standard technique. Pulmonary artery and right
ventricular pressures were recorded with a Gilson recorder by
slowly pulling back the catheter and observing the pressure
configuration. The pressure tracings were coded, and examined
blindly of all other data.
On the day of sacrifice of the dogs, thoracotomy was performed
and tissue specimens of the lung were obtained. The specimens
were first washed with normal saline, blotted with filter paper and
then placed in a tared crucible. The latter was weighed to 0.01 mg
to determine wet weight and then dried at 105°C for 48 hours. The
tissues were reweighed to determine water content and was then
brought to dry ash at 550° for 24 hours. The samples were then
extracted in 0.75 N nitric acid for 24 hours and measurements of
calcium were made in the supernatant. All data are presented as
the mean 1 sE; statistical comparisons within the groups were
performed by paired and between the groups by unpaired Stu-
dent's t-test.
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Table 1. Body weights and biochemical data in normal animals, CRF, and CRF-PTX dogs before and after CRF
Normal
dogs
CRF CRF-PTX
B A B A
Weights kg 19.8 0.6 21.2 0.6 20.5 0.2 21.0 0.6 20.3 0.7
Duration of CRF weeks — — 60.0 2.5 — 58.7 2.8
Creatinine clearance mI/mm 58.2 1.2 60.0 1.3 14.0 39a 59.3 2.5 13.3 2.8a
Plasma sodium mEqlliter 146.0 0.6 148.0 1.1 146.0 1.3 149.0 0.6 147.0 0.7
Plasma potassium mEqiliter 4.2 0.2 4.3 0.1 4.6 0.1 4.4 0.1 4.5 0.1
Plasma bicarbonate mEqiliter 22.3 0.4 22.0 0.6 20.2 0.5 23.0 0.6 21.0 0.6
Plasma calcium mg/dl 10.3 0.2 10.0 0.2 10.2 0.5 9.9 0.1 10.0 0.2
Phosphorous mg/dl 4.2 0.1 4.3 0.3 4.5 0.3 4.4 0.3 4.5 0.2
Calcium-phosphorous product 43.0 1.9 44.0 2.6 45.0 2.3 45.0 2.6 46.0 2.3
Plasma magnesium mgldl 1.90 0.6 1.92 0.6 1.98 0.6 1.97 0.7 1.96 0.6
Free thyroxine index 2.08 0.6 2.13 0.07 2.0 0.06 2.1 0.06 2.02 0.06
PTH iilEq/ml 13.0 3.3 15.0 2.2 165.0 21b 14.6 2.1 UD
Data are presented as means 1 SE. Abbreviations are: B, before CRF; A, after CRF.
ap < 0.01 versus values before CRF
'P < 0.01 versus all other PTH values
Table 2. Weights, biochemical data, P02, P0, and diffusing capacity of
lungs (DCO) in dogs with CRF of one year duration (CRF), followed
by parathyroidectomy and an additional year of CRF (CRF-PTX)
Baseline CRF CRF-PTX
Weight kg 21.7 0.9 22.0 0.9 21.7 0.5
Creatinine clearance mI/mm 54.0 1.2 14.0 1.2 11.0 0.6
Plasma sodium mEqiliter 149 0.7 147 1.2 145 0.7
Plasma potassium mEq/liter 4.1 0.2 4.0 0.1 3.9 0.2
Plasma bicarbonate mEqiliter 23.0 0.6 22.3 0.9 21.3 0.9
Plasma calcium mg/dl 10.3 0.2 10.2 0.2 10.0 0.1
Plasma phosphorous mg/dl 3.7 0.1 4.0 0.2 4.1 0.1
Calcium-phosphorous product 39.3 1.1 40.3 0.9 40.6 0.7
Magnesium mg/dl 2.1 0.1 2.0 0.1 2.1 0.06
Free thyroxine index
Serum PTH j.dEq/ml
2.13 0.9
16 3.2
2.2 0.06
187 22b
2.1 0.02
UD
Blood P02 mm Hg 52.0 1.4 51.0 0.8 53.2 0.7
Blood Pc02 mm Hg 39.0 1.5 40.0 1.4 39.7 0.9
DCO mI/mm/mm Hg 8.2 0.6 2.8 0.6a 8.3 0.4
Calcium content of lung — — 966 12
mg/kg/thy wt
1 SE.Data are presented as mean
aP < 0.01 versus baseline and CRF-PTX
hP < 0.01 versus all other PTH levels
Results
The biochemical data in all groups of animals studied are given
in Table 1. There were no significant differences between the
weights of the dogs, the duration of CRF, the creatinine clearance
levels, the concentration of the various biochemical parameters
(except for the serum levels of PTH) between CRF and CRF-PTX
dogs both before and at the end of the CRF period. The 5/6
nephrectomy resulted in marked and significant (P < 0.01)
reduction in creatinine clearance. The serum concentration of
PTH in dogs with intact parathyroid glands was 165 21 .tlEq/m1,
and the values in individual dogs were 8 to 25 times higher than
mean normal values. The serum levels of PTH were undetectable
in the CRF-PTX dogs.
Table 2 provides the data on those dogs which were parathy-
roidectomized after one year of CRF and followed for additional
one year. Again there was no significant differences between the
values of the various parameters at the end of one year of CRF
and those obtained after the end of an additional year following
PTX. However, the serum levels of PTH which were significantly
(P < 0.01) elevated at the end of one year of CRF became
undetectable after the PTX of these animals.
The results of thallium scan studies provided evidence consis-
tent with right ventricular hypertrophy in all the CRF dogs but not
in CRF-PTX animals (Fig. 1).
The data of RVP, MPAP, DCO, and calcium content of lungs
are given in Table 3. RVP values in CRF dogs ranged between 30
and 45 (36 2.1) mm Hg which are significantly elevated
compared to values in normal dogs which ranged between 15 and
25 (19 1.5) mm Hg, and those observed in CRF-PTX animals
which ranged between 15 and 25 (22 2.0) mm Hg. The values of
RVP in normal and CRF-PTX dogs were not different. MPAP
ranged from 20 to 31(24 1.7) mm Hg in the CRF animals; these
values were significantly (P < 0.01) higher than those observed in
normal dogs [range 10 to 14 (12 0.6) mm Hg] and those in
CRF-PTX animals [range 12 to 18 (14 1.1) mm Hg. The mean
values for P02 and P02 in normal, CRF, and CRF-PTX were not
different (Table 3). DCO was significantly (P < 0.01) impaired in
CRF dogs ranging between 2.0 and 4.0 (3.0 0.3) mI/mm/mm Hg.
The value in normal dogs ranged from 7.5 to 16.8 (11.0 1.4) and
in CRF-PTX animals it ranged from 11.8 to 19.1 (12.0 1.5)
ml/min/mm Hg. The values in latter two groups were not different.
The calcium content in the lungs of CRF animals ranged from
2600 to 12335 (7656 1657 mg/kg/dry wt), and these values were
significantly (P < 0.01) higher than in normal animals [range 560
to 800 (673 34) mg/kg/dry wtj, and those in CRF-PTX animals
[range 600 to 1440 (1057 117) mg/kg/dry wt]. However, the
values in CRF-PTX dogs were modestly but significantly (P <
0.01) higher than those in normal dogs.
The data on P02, Pc02, DCO and calcium content of lungs in
the three dogs with CRF of one year duration which were then
subjected to thyroparathyroidectomy and followed for an addi-
tional year are given in Table 2. There were no significant
differences in P02 and P02 before, at one year of chronic renal
failure (CRF), and at the end of another year of CRF and PTX.
PTX corrected the abnormality in DCO. Furthermore, the cal-
cium content of the lungs was significantly (P < 0.01) lower than
that observed in CRF dogs and not different from the other
CRF-PTX dogs; the values, however, were still modestly but
significantly higher than those in normal dogs.
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Fig. 1. Thallium scan in a CRF dog illustrates abnormal visualization of right ventricle (as shown by the arrows, right panel), while this abnormality is not
observed in thallium scan of a CRF-PTX dog (left panel).
Table 3. P02, P02, diffusing capacity of lungs (DCO), right ventricular
pressure (RVP), mean pulmonary artery pressure (MPAP), and calcium
content of the lungs in control, CRF, and CRF-PTX dogs
Normal CRF CRF-PTX
P02mmHg
Pc0 mmHg
DCó mI/mm/mm Hg
50±2.2
44±3.1
11 1.4
46± 1.9
40±1.4
3 1.la
47±3.3
40±0.9
12 1.5
RVP mm Hg 19 1.5 36 2.1 22 2.2
MPAPmmHg 12±0.6 24±1.7a 14±1.1
Calcium content of the lungs 673 34 7656 1657k' 1057 117
mg/kg/thy wt
Data are presented as mean 1 sa.
a P < 0.01 versus normal
bp < 0.01 versus normal and CRF-PTX
Discussion
The results of the present study demonstrate that CRF of one
year duration or more in dogs is associated with significant
increment in calcium content of the lungs. It appears that this
accumulation of calcium is mediated, in large part, by the state of
secondary hyperparathyroidism of CRF. Indeed CRF-PTX dogs
of similar degree and duration of CRF had only modest increment
in calcium content of lungs. Our observation on calcium content
of the lung is in agreement with previous reports showing that
calcium content of brain [22], heart [20, 211, pancreas [25], skin
[18, 19], cornea [17], and liver [23] are increased in animals or
humans with CRF and excess PTH; PTX in CRF animals either
prevented or markedly mitigated the increment in the calcium
content of these tissues.
PTH augments calcium entry into many cells [11—16], and
chronic exposure to excess PTH even in the absence of CRF is
associated with marked and significant rise in basal levels of
[Ca2] of many cells [26]. However, this elevation in [Ca2]1
could not account for the significant increment in total calcium
content in CRF, as seen as in lungs and many other organs such
as heart [27], pancreas [28], and brain [29]. Therefore, one must
consider that the increment in total calcium content is also due to
the deposition of calcium salts in extracellular matrix of these
organs. Such deposition of calcium salts is mainly due to excess
PTH, since the calcium content of these organs is significantly
reduced in CRF-PTX animals. One must, therefore, consider
other consequences of excess PTH such as hyperphosphatemia
leading to increased calcium-phosphorous product as a potential
cause of the increase in calcium content. In our study the plasma
phosphorous levels were measured after 16 hours of overnight fast
at least six times during the period of CRF, and these measure-
ments did not display hyperphosphatemia. However, it is possible
that hyperphosphatemia occurred at other times and also after
meals, leading to transient increase in calcium-phosphorous prod-
uct and consequently to calcium deposition. One should also
consider that plasma phosphorous was better controlled in the
CRF-PTX animals since they were ingesting calcium carbonate,
an agent that binds phosphorous in the intestine. Finally local
tissue injury and alteration in intracellular pH in CRF may
predispose to calcium precipitation in tissues [30]; one or both of
these factors could have contributed to the modest increments in
calcium content of lungs from PTX dogs with CRF.
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Thus the data of our studies in dogs are in agreement with
reports in humans with CRF in that the latter are associated with
pulmonary calcification. Our data also provide evidence for the
important role for the state of secondary hyperparathyroidism of
CRF in the genesis of this abnormality.
The results of the present study clearly demonstrate that CRF
is associated with reduced pulmonary diffusing capacity, and this
abnormality is due to the marked pulmonary calcification, since
CRF-PTX animals with only modest increment in lung calcium
had normal lung diffusing capacity despite CRF. It is of interest to
note that the rise in lung calcium in CRF could be potentially
reversible. This notion is supported by the results of the studies in
three dogs who had CRF and elevated levels of PTH for a year
and were then subjected to PTX and followed for another year.
Both the calcium content and the diffusing capacity of the lung
were restored by the correction of secondary hyperparathyroid-
ism.
Data on pulmonary function in patients with CRF are limited.
Cogner et a! [3] studied pulmonary calcification and attempted to
correlate it with potential derangements in ventilatory function in
31 dialysis patients. They found that restrictive ventilatory defects,
decreased diffusion and hypoxia were frequently present in those
patients who had severe pulmonary calcification. These abnormal-
ities were absent in patients who did not have evidence of
pulmonary calcification. Similarly, Faubert et al [5] found im-
paired DCO in 7 of the 10 dialysis patients who had positive
99mTcDp and in none of the patients with negative scans. Thus,
the observations of both Cogner et al [3] and Faubert et al [5] also
assign an important role of pulmonary calcification in the genesis
of functional derangements in pulmonary function in CRF pa-
tients.
Many studies have evaluated left ventricular function in pa-
tients with CRF and in those treated with hemodialysis [3 1—35].
These data show that these patients may have left ventricular
hypertrophy, reduced myocardial contractibility, enlargement of
left ventricular cavity, higher ventricular radius to wall thickness
ratio, and congestive heart failure. It is of interest that several
studies have demonstrated that medical [36] or surgical [36, 37]
control of secondary hyperparathyroidism of CRF was followed
by significant improvement in left ventricular function. Even in
the absence of renal insufficiency, PTH may participate in the
genesis of left ventricular hypertrophy in patients with primary
hyperparathyroidism [38, 39]. Also, a correlation between blood
levels of PTH and left ventricular hypertrophy has been reported
in patients with hypertension and normal renal function [40].
The results of the present study add new dimension to the
overall characteristics of cardiac dysfunction in CRF. They dem-
onstrate that the right ventricular function could also be deranged
in CRF in that right ventricular pressure is elevated and right
ventricular hypertrophy is present. These derangements were
prevented by prior PTX of the CRF dogs. It is, therefore,
proposed that the abnormalities in right ventricular function, in
large part, are due to pulmonary hypertension which develops
secondary to pulmonary calcification. Indeed, the prevention of
pulmonary calcification by parathyroidectomy of CRF dogs was
associated with normalization of MPAP and absence of right
ventricular hypertrophy. Thus, it appears that excess PTH in CRF
adversely affects both the left and right ventricles.
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